-

01:03:51 AM

EDSA Stock News

EDSA - Edesa Biotech Inc

01/13/22 7:55 AM

Nasdaq : EDSA

covid-19low float

Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today

RHEA-AI

neutral

12/28/21 4:15 PM

Nasdaq : EDSA

earningslow float

Edesa Biotech Reports Fiscal Year 2021 Results

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the fiscal year ended September 30, 2021 and provided an update on its business.

RHEA-AI

very positive

12/01/21 7:58 AM

Nasdaq : EDSA

low float

Edesa Biotech Marks Enrollment Milestone in Dermatitis Study

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of more than 75% of the patients planned for the primary cohort of a

RHEA-AI

neutral

11/04/21 8:00 AM

Nasdaq : EDSA

clinical trialcovid-19low float

Edesa Biotech Extends COVID-19 Clinical Study to Poland

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related

RHEA-AI

neutral

10/19/21 8:00 AM

Nasdaq : EDSA

covid-19low float

Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study

Edesa Biotech, Inc. (NASDAQ:EDSA), a

RHEA-AI

negative

09/20/21 8:00 AM

Nasdaq : EDSA

clinical trialcovid-19low float

Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients

RHEA-AI

neutral

09/09/21 7:00 AM

Nasdaq : EDSA

conferenceslow float

Edesa Biotech to Present at the H.C. Wainwright Global Investment Conference

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global

RHEA-AI

neutral

08/26/21 7:30 AM

Nasdaq : EDSA

covid-19low float

Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage

RHEA-AI

neutral

08/13/21 7:50 AM

Nasdaq : EDSA

earningslow float

Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and nine months ended June 30, 2021 and provided an update on its business.

RHEA-AI

very positive

07/13/21 8:10 AM

Nasdaq : EDSA

low float

Edesa Biotech Extends Dermatitis Study to Canada

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company has expanded patient enrollment to Canada for the final part of a Phase 2b study evaluating

RHEA-AI

neutral

EDSA Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.edesabiotech.com
Security nameEdesa Biotech Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees12
Tags
- Biotechnology
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing

EDSA Description:

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that it's developing as a treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. The company is based in Markham, Ontario, Canada, with a U.S. subsidiary located in Southern California.